Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Stem cell techniques set to reduce false positives

Kalorama Information : 20 March, 2008  (Company News)
More than 90 percent of drugs entering clinical development fail to reach the market, due to the lack of effectiveness or adverse side effects not detected in animal tests reports to Kalorama Information in a new publication entitled ‘Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development’.
These false positives could be avoided with pre-clinical tests using stem cell technologies, potentially saving drug developers millions.

The discovery and commercialisation of a new drug costs in excess of $1 billion and requires more than 14 years. Early toxicity testing is a particular problem, since there are currently no good models for determining whether a drug will be toxic in humans. Some unsafe products advance through testing and approval, only to be pulled from the market later at a huge expense, as was the case with Vioxx and Bextra.

Though stem cell-based drug development technologies are in an early stage of development, and will most likely not become available before 2012 at the earliest, their prospects are promising.

“The excitement around stem cells has understandably been in the potential for therapy, but drug development is where they may have the most impact on healthcare.” noted Bruce Carlson, publisher of Kalorama Information. “Stem cell technology could provide a virtually endless supply of liver or heart cells for testing, saving developers tens, if not hundreds of millions of dollars in direct testing fees, as well as indirect costs related to drug recalls.”

Recognizing stem cells’ potential, GlaxoSmithKline, AstraZeneca and Roche established a new venture in 2007, Stem Cells for Safer Medecines, to develop effective ways of using human ES cells to screen for potentially dangerous side effects of new drugs before they go into clinical trials.

Kalorama Information’s report ‘Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development’ discusses critical issues and trends in this exciting new field. The information and forecasts presented through 2020 were gathered through secondary research and interviews conducted with industry executives.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 ProHealthServiceZone.com
Netgains Logo